Merck gets FDA ok for Zostavax shingles vaccine

MichaelBaron

NEW YORK (MarketWatch) -- Merck & Co. Inc.
MRK, -1.03%
Friday received approval of Zostavax for the prevention of shingles in adults age 60 and older from the Food and Drug Administration. The Dow component said the vaccine is available for ordering by physicians and it expects to begin shipping soon. The Whitehouse Station, N.J. drug giant listed the catalog price for a ten-pack of single-dose vials at $145.35. The stock closed Thursday at $34.39, up 1.3%.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.